Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 258-263 , July 2007

The Effect of n-3 Fatty Acids on C-Reactive Protein Levels in Patients With Chronic Renal Failure

  • Trine Madsen, MD

      Affiliations

    • Department of Cardiology and Cardiovascular Research Centre, Aalborg Hospital, Århus University Hospital, Aalborg, Denmark.
    • Corresponding Author InformationAddress reprint requests to Trine Madsen, MD, Cardiovascular Research Centre, Aalborg Hospital, PO Box 365, 9100 Aalborg, Denmark.
    • ,
  • Erik B. Schmidt, MD, DMSc

      Affiliations

    • Department of Cardiology and Cardiovascular Research Centre, Aalborg Hospital, Århus University Hospital, Aalborg, Denmark.
    • ,
  • Jeppe H. Christensen, MD, DMSc

      Affiliations

    • Department of Nephrology, Aalborg Hospital, Århus University Hospital, Aalborg, Denmark.

References 

  1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119
  2. Shoji T, Emoto M, Tabata T, et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002;61:2187–2192
  3. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  4. Jungers P, Khoa TN, Massy ZA, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. Nephrol Dial Transplant. 1999;14:898–902
  5. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  6. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362
  7. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818
  8. Zebrack JS, Anderson JL, Beddhu S, et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency?. J Am Coll Cardiol. 2003;42:57–63
  9. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  10. Schmidt EB, Pedersen JO, Varming K, et al. n-3 fatty acids and leukocyte chemotaxis (Effects in hyperlipidemia and dose-response studies in healthy men). Arterioscler Thromb. 1991;11:429–435
  11. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  12. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  13. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–636
  14. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  15. Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, et al. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol. 2000;53:115–123
  16. Anderson MM, Requena JR, Crowley JR, et al. The myeloperoxidase system of human phagocytes generates Nepsilon- (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103–113
  17. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–1842
  18. Stenvinkel P, Heimburger O, Jogestrand T, et al. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure?. Kidney Int. 1999;55:2531–2532
  19. Ridker PM, Rifai N, Pfeffer MA, et al. The Cholesterol and Recurrent Events (CARE) Investigators Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  20. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  21. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–348S
  22. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001;36:1007–1024
  23. Lee TH, Austen KF. Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Adv Immunol. 1986;39:145–175
  24. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–348S
  25. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–348S
  26. Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996;63:116–122
  27. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71:213S–223S
  28. Schmidt EB, Pedersen JO, Varming K, et al. n-3 fatty acids and leukocyte chemotaxis (Effects in hyperlipidemia and dose-response studies in healthy men). Arterioscler Thromb. 1991;11:429–435
  29. Fiedler R, Mall M, Wand C, et al. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr. 2005;15:253–256
  30. Madsen T, Skou HA, Hansen VE, et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol. 2001;88:1139–1142
  31. Nielsen GL, Faarvang KL, Thomsen BS, et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial. Eur J Clin Invest. 1992;22:687–691
  32. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35:772–781
  33. Madsen T, Christensen JH, Blom M, et al. The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Br J Nutr. 2003;89:517–522
  34. Vega-Lopez S, Kaul N, Devaraj S, et al. Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism. 2004;53:236–240
  35. Geelen A, Brouwer IA, Schouten AG, et al. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr. 2004;58:1440–1442
  36. Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155–160

PII: S1051-2276(07)00094-5

doi: 10.1053/j.jrn.2007.03.003

Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 258-263 , July 2007

Article Tools

* Image Usage & Resolution